𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS Clinical Trial

✍ Scribed by Yuzuru Kanakura; Kazuma Ohyashiki; Tsutomu Shichishima; Shinichiro Okamoto; Kiyoshi Ando; Haruhiko Ninomiya; Tatsuya Kawaguchi; Shinji Nakao; Hideki Nakakuma; Jun-ichi Nishimura; Taroh Kinoshita; Camille L. Bedrosian; Marye Ellen Valentine; Gus Khursigara; Keiya Ozawa; Mitsuhiro Omine


Publisher
Carden Jennings Publishing
Year
2011
Tongue
English
Weight
307 KB
Volume
93
Category
Article
ISSN
0925-5710

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Long-term effect of the complement inhib
✍ Peter Hillmen; Modupe Elebute; Richard Kelly; Alvaro Urbano-Ispizua; Anita Hill; πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 140 KB πŸ‘ 2 views

## Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is a debilitating and life‐threatening disease in which lysis of PNH red blood cells frequently manifests with chronic hemolysis, anemia, and thrombosis. Renal damage in PNH is associated with chronic hemosiderosis and/or microvascular thrombosi